Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
April 25, 2024 at 06:32 AM EDT
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Photography by Christophe Tomatis